Yes, Loxo is still planning on seeking an accelerated OK, in case you had forgotten
Back in the spring, Loxo Oncology $LOXO was ready to pounce with an early snapshot of some clinical responses to its lead cancer drug, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
